OOIR: Observatory of International Research

Papers

(The median citation count of JAMA Oncology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Induction Chemotherapy for Advanced Nasopharyngeal Carcinoma—Is This the New Standard of Care?	1518
JAMA Oncology	637
Insights Into Immune-Mediated Disease and Cancer Risk—Delivering on the Promise of UK Biobank Big Data	352
Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer	322
Analysis of Quality-of-Life Outcomes by Drug Class in Cancer Clinical Trials—Reply	282
Error in Text	277
Errors in Key Points and Abstract	259
Stargazers	256
Biomarker Analysis of Vistusertib Plus Paclitaxel Regimen	249
Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants	248
Sexual Rehabilitation Needs of Gay and Bisexual Men With Cancer	246
Active Cellular Immunotherapy in the Desert of Advanced Prostate Cancer	228
Overall Survival in the CAIRO5 Clinical Trial	206
Piercing the Fog	195
The Implications of the Supreme Court Decision to Overturn Roe v Wade for Women With Pregnancy-Associated Cancers	190
Established Cancer Predisposition Genes in Single and Multiple Cancer Diagnoses	188
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults	184
Diversity Trends by Sex and Underrepresented in Medicine Status Among US Radiation and Medical Oncology Faculty Over 5 Decades	170
Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab	159
The Multidisciplinary Cancer Conference	158
Firearm Safety for Patients Diagnosed With Cancer—A Role in Suicide Prevention	154
Unrelated Donor Age and Recipient Outcomes After Posttransplant Cyclophosphamide vs Conventional Prophylaxis	154
Audit of Data Sharing by Pharmaceutical Companies for Anticancer Medicines Approved by the US Food and Drug Administration	139
Concerns Regarding the Utility of High-Risk Pancreatic Cancer Surveillance—Reply	138
Immunotherapy in Prepatients—Preventing or Promoting a Malignant Transformation?	136

Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors	135
The Global Economic Cost of Cancer—Estimating It Is Just the First Step!	134
Limitations in Quantitative Harm-Benefit Assessment in Immuno-Oncology	132
Nationwide Response to Carboplatin and Cisplatin Shortages in Lung Cancer	132
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer	129
Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ ERBB2 -Negative Early Breast Cancer	123
Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia	119
Her Defiance	116
Systemic Anticancer Therapy and Overall Survival in Patients With Very Advanced Solid Tumors	115
Long-term Effect of Machine Learning–Triggered Behavioral Nudges on Serious Illness Conversations and End-of-Life Outcomes Among Patients With Cancer	113
Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab	113
Methodology Concerns Regarding Claims Data Studies in Transgender Health—Reply	112
Internal Mammary Nodal Irradiation Debate for Node-Positive Breast Cancer—Has the Needle Moved?—Reply	111
SARS-CoV-2 Infections, Hospitalizations, and Mortality in Vaccinated Patients With Cancer in the US	110
Association of 5α-Reductase Inhibitor Use With Prostate Cancer–Specific Mortality—Reply	106
Use of Participation to Prevalence Ratio for Evaluating the Representation Status of Women in Oncology Clinical Trials—Reply	104
The SOUND Randomized Clinical Trial Results	101
Results of the TARGET-TP Randomized Clinical Trial	100
Variability in COVID-19 Vaccine Response Among People With Cancer	97
Is Appendiceal Cancer a Lynch Syndrome–Associated Cancer?	96
An Atypical Rash on the Chest	96
Immunotherapy Before Chemoradiotherapy—More Is Better?	93
Unplanned Hospitalization Prediction During Chemoradiotherapy Via Machine Learning Classifiers—Reply	91
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer	90
Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor–Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation	90
Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers	89
Trends in the Characteristics, Treatment, and Outcomes of Rectal Adenocarcinoma in the US From 2004 to 2019	88
Natural Language Processing–Assessed Unmet Medical and Social Needs in Cancer Crowdfunding Stories	87
Association Between Age and Survival Trends in Advanced Non–Small Cell Lung Cancer After Adoption of Immunotherapy	86
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?	86
Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis	83
Anti–Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma	81
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent	81
Clinical Trial Diversity—Will We Know It When We See It?	81
Effect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size	80
Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China	80
Shifting Toward Precision Oncology in SCLC Treatment	80
Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer	79
JAMA Oncology	79
The Most Difficult Lesson From Cancer Just Might Be Its Most Valuable	79
Trauma	79
Accelerated Approval Is Not Conditional Approval	78
Coding Errors in Study of Eligibility for Lung Cancer Screening	78
Error in Text	77
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	75
Disparities in Trends of Gastroenteropancreatic Neuroendocrine Tumor Incidence	75
JAMA Oncology	75
Steroid Dose and Duration, Immortal Time Bias, and Survival After High-grade Immune-Related Adverse Events—Reply	75
Proton Craniospinal Irradiation for Patients With Leptomeningeal Metastasis	74
Magnetic Resonance Imaging or Confirmatory Biopsy for Patients With Prostate Cancer Receiving Active Surveillance	74

Rethinking End Points in Modern Oncology Trials—Beyond the P Value	73
Unwinding of Medicaid Continuous Enrollment Exposes Millions to Disrupted Care—“Be Kind, Rewind”	73
National Trends in Dexrazoxane and Cardiovascular Health Care Utilization for Children With Acute Myeloid Leukemia	71
Noninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms	70
Prostate-Specific Membrane Antigen PET-Guided Intensification of Salvage Radiotherapy After Radical Prostatectomy	70
Second Primary Cancer After Chimeric Antigen Receptor–T-Cell Therapy	69
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer	69
Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer	69
BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients	69
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma	68
On Accelerated Aging—A Phenomenon in Survivors of Childhood Cancer	67
Measurable Residual FLT3 Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia	67
Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Don	67
Undiagnosed Cancer Cases in the US During the First 10 Months of the COVID-19 Pandemic	67
Is the Delphi’s Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma?—Reply	65
Does Circulating Tumor DNA Measure Up to Prostate-Specific Antigen?	65
Change of Article Status to Open Access	65
JAMA Oncology	65
Methodological Issues in Study of Daily Insulin Dose and Cancer Risk Among Patients With Type 1 Diabetes	64
Neoadjuvant mFOLFIRINOX vs mFOLFIRINOX Plus Radiotherapy in Patients With Borderline Resectable Pancreatic Cancer—The A021501 Trial—Reply	63
Exposure Histories and Cancer Risk—What Can We Learn?	62
JAMA Oncology Peer Reviewers in 2021	61
Challenges in Shared Care Research in Hematopoietic Cell Transplantation—Reply	60
Role of Patient-Reported Outcome Measures in the Inpatient Setting—Reply	60
JAMA Oncology	60
Standardized Definitions for Efficacy End Points for Adjuvant Trials—The Updated STEEP Criteria	60
“You’ve Got Mail”—Receiving Bad News Through a Patient Portal	60
Analysis of Association of Radiation Therapy With Risk of Adverse Events in Patients Receiving Immunotherapy Using Pooled Trial Data Matched by Propensity Score	60
Activity of Cabazitaxel in Metastatic or Inoperable Locally Advanced Dedifferentiated Liposarcoma	59
Searching Beyond Programmed Cell Death Ligand 1 in Metastatic Breast Cancer—Still Haven’t Found What We’re Looking For	59
Caution Regarding Assessment of Toxic Effects and Survival in Treatment De-escalation With Radiotherapy vs Transoral Surgery for Human Papillomavirus–Associated Oropharyngeal Cancer	58
Self-reported Transportation Barriers to Health Care Among US Cancer Survivors	58
The ORATOR Trials Have Spoken—Where Do We Go From Here?	57
Consistent Adherence to Physical Activity Guidelines and Digestive System Cancer Risk and Mortality	57
Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor–Positive Breast Cancer	57
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Non−Small Cell Lung Cancer	56
Rates of and Factors Associated With Patient Withdrawal of Consent in Cancer Clinical Trials	55
Artificial Intelligence–Detected Tumor-Infiltrating Lymphocytes and Outcomes in Anti–PD-1–Based Treated Melanoma	55
Treatment of Adults With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia—From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens	55
Association of Genetic Ancestry With the Molecular Subtypes and Prognosis of Childhood Acute Lymphoblastic Leukemia	55
Effect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer	55
Dose-Adjusted EPOCH Plus Inotuzumab Ozogamicin in Adults With Relapsed or Refractory B-Cell ALL	54
Characterizing Lung Cancer in Li-Fraumeni Syndrome	54
Pembrolizumab or Placebo Plus Chemotherapy With or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer	53
The Children’s Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers	53
Endocrine Society Hypercalcemia of Malignancy Guidelines	53
Duration and Dose of Adjuvant Zoledronic Acid for Treatment of Early Breast Cancer—Reply	52
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer	52
Global Stage Distribution of Breast Cancer at Diagnosis	52
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma	52
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer	52
Sunsets	51
JAMA Oncology	50
JAMA Oncology	49
Should DDGP Regimen Be the Standard of Care for Advanced Extranodal NK/T-Cell Lymphoma? The New Staging System Matters	49
Overall Survival With Adjuvant mFOLFIRINOX for Pancreatic Cancer	49
The Oncology Industrial Complex—Community Oncology Must Be Given a Seat at the Table—Reply	48
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction—Reply	48
Oral Mucosal Pigmentation in a Patient With Mycosis Fungoides	48
Valid Analysis of Brain-Specific Progression-Free Survival	48
Artificial Intelligence—From Starting Pilots to Scalable Privilege	47
Personalized Radiation Therapy—Spurning the “One Size Fits All” Approach	47
Errors in Figures 2 and 3	47
Radiotherapy With a 12-Gene Expression Assay for Ductal Carcinoma In Situ	46
Effect of a Symptom Monitoring Intervention for Patients Hospitalized With Advanced Cancer	46
Association of Patient-Reported Outcomes With Subsequent Nonfatal Self-injury After a New Cancer Diagnosis	46
Relentless	46
Effect of Capecitabine Maintenance Therapy Plus Best Supportive Care vs Best Supportive Care Alone on Progression-Free Survival Among Patients With Newly Diagnosed Metastatic Nasopharyngeal Carcinoma	46
Management of Down Syndrome–Associated Leukemias	46
Managing Cancer Pain in Patients With Opioid Use Disorder or Nonmedical Opioid Use	45
Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer	45
Recurrence of Non–Small Cell Lung Cancer With Visceral Pleural Invasion	45
Exploration of Clinician Perspectives on Multidisciplinary Tumor Board Function Beyond Clinical Decision-making	45
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer—Reply	45
Public Awareness of the Association Between Alcohol and Cancer in the US	45
Comparing Risk for Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer, 2002-2015	44
Reshuffle	44
Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer	44
Effectiveness of Aerobic Exercise and Tai Chi Interventions on Sleep Quality in Patients With Advanced Lung Cancer	44
MGMT Promoter Methylation and Chemotherapy Outcomes in Low-Grade and Anaplastic Gliomas	44

Error in Denominator in Results Text	44
Smoking Status of the US Cancer Population and a New Perspective From the National Cancer Database	44
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer	44
Shared Local Oncology Care After Allogeneic Hematopoietic Cell Transplantation	43
JAMA Oncology	43
Assessment of Phase 3 Randomized Clinical Trials Including Patients With Leptomeningeal Disease	43
Immune Checkpoint Inhibitor Therapy Before Nephrectomy for Locally Advanced and Metastatic Renal Cell Carcinoma	43
Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer	43
Scattered Painful Papulonodules in an Older Woman	42
Integrating Community Health Workers Into Care for Patients With Advanced Stages of Cancer—Fragility Index Analysis	42
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer	42
Advancing Truth in Oncology by Complementing Clinical Trials With Evidence From Clinical Practice	42
Dog Aloisanov Helped Diagnose My Cancer	41
Errors in Figure 3	41
The SOUND Randomized Clinical Trial Results—Reply	41
Two Hands, One Journey	41
Change of Article Status to Open Access	41
Error in Figure	40
Error in Figure 1	40
Locally Advanced Relapse May Not Be Equal to Stage 3 Non–Small Cell Lung Cancer	40
Stereotactic Radiosurgery vs Conventional Radiotherapy for Spine Metastases	40
Carboplatin During Craniospinal Radiotherapy for Children With Group 3 Medulloblastoma—A New Standard of Care?—Reply	39
Somebody Else’s Palms	39
An Algorithm as a Biomarker for Response to Immune Checkpoint Inhibitor Therapy	39
The Case for Allowing Proton Beam Therapy on Head and Neck Cooperative Group Studies	39
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients	39
Error in Figure 1	39
Financial Toxicity Among Asian American Cancer Survivors	39
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction	39
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer	39
Postoperative Restrictive Opioid Protocols and Durable Changes in Opioid Prescribing and Chronic Opioid Use	39
Unintended Consequences of Patient Portal Access	39
Cervical Cancer Incidence in the US-Affiliated Pacific Islands	38
Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive Early Breast Cancer	38
Is Regional Nodal Radiotherapy Necessary for Patients With cN1 and ypN0 Breast Cancer After Neoadjuvant Chemotherapy?—Reply	38
Risk Factors for Valvulopathy Among Childhood Cancer Survivors	38
Increasing the Uptake of Cancer Risk Management Strategies for Women With BRCA1/2 Sequence Variations	38
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma	38
Integrating Oncology Lessons Across Tumor Types From Kidney to Prostate—A Good-Risk Shift	38
Genetic Ancestry–Based Differences in Biomarker-Based Eligibility for Precision Oncology Therapies	37
Use of Single-Arm Trials for US Food and Drug Administration Drug Approval in Oncology, 2002-2021	37
Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy	37
PARP Inhibitors for Breast Cancer Treatment	37
Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases	37
Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer	37
An Intramedullary Enigma	36
Change to Open Access Status	36
Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non–Small Cell Lung Cancer—Reply	36
Error in Author Surname	36
Comment on Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer	35
JAMA Oncology	35
Is 2045 Optimistic?—Concerns Regarding Rising Vaccine Hesitancy—Reply	35
Racial Disparities and Survival Outcomes in Breast Cancer—Reply	35
A Case of Multiple Hemorrhagic Friable Nodules	35
Error in the Additional Contributions Section	34
Patient Harassment of Medical Trainees	34
Duration and Dose of Adjuvant Zoledronic Acid for Treatment of Early Breast Cancer	34
Change to Open Access	34
Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck—Reply	34
Government Funding for the Development of Enzalutamide	34
Long-Term Toxicity of Immune Checkpoint Inhibitors—Time to Widen the Lens	33
Overall Survival in the CAIRO5 Clinical Trial	33
Implementing Smoking Cessation Interventions for Tobacco Users Within Oncology Settings	33
SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents	32
Implementing Resource-Stratified Guidelines in LMICs—More Issues Than Solutions	32
Childhood Cancer Survivor Risk Estimates and Age, Overdispersion, and Social Context—Reply	32
USPSTF Lung Cancer Screening Guidelines and Disparities in Screening Adherence	32
Charting the Path to Systemic Therapy De-escalation—Oligometastatic Kidney Cancer as a Paradigm	32
High-Dose Aumolertinib for Untreated EGFR-Variant Non–Small Cell Lung Cancer With Brain Metastases	32
Reexamining Social Determinants of Health Data Collection in the COVID-19 Era	32
Atezolizumab and Trastuzumab Plus Chemotherapy for ERBB2-Positive Locally Advanced Resectable Gastric Cancer	31
Tepotinib Treatment in Patients With MET Exon 14–Skipping Non–Small Cell Lung Cancer	31
Blood Clots, or Thrombosis, in Patients With Cancer	31
Enhancing Clinical Cancer Research Through Sharing of Data and Biospecimens	31
The Urgent Need for Affordability Curricula at US Medical Schools	31
Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer	30
Effect of Apatinib Plus Pegylated Liposomal Doxorubicin vs Pegylated Liposomal Doxorubicin Alone on Platinum-Resistant Recurrent Ovarian Cancer	30
Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2	30
A Paradigm Shift Toward Population-Based MRI-Targeted Prostate Cancer Screening	30
Lazertinib in EGFR-Variant Non–Small Cell Lung Cancer With CNS Failure to Prior EGFR Tyrosine Kinase Inhibitors	30
Osimertinib in Patients With Non–Small Cell Lung Cancer and Uncommon EGFR Mutations—Chasing Unicorns?	30
Association of Second-generation Antiandrogens With Cognitive and Functional Toxic Effects in Randomized Clinical Trials	30
Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue	30
Immunotherapy Strategies After Immune Checkpoint Inhibitor Exposure in Renal Cell Carcinoma	30
Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma	29
Aiming for the Cure in ERBB2-Positive Metastatic Breast Cancer—Should We Go “All In”?	29
JAMA Oncology—The Year in Review, 2023	29
Watch and Wait for Near-Complete Responders—A Word of Caution	29
Errors in Byline	29
Results of the TARGET-TP Randomized Clinical Trial—Reply	29
Concerns Remain Regarding the Association of Sitting Time and Physical Activity With Cancer Survivorship	29
Nontumor Cells in Tumor Samples Bias Expression-Based Models	29
Keeping the Heartbeat Off-Target in Cancer Therapy	29
Assessment and Prognostic Value of Inflammatory Biomarkers in Patients With Colon Cancer	29
PSMA PET in Prostate Cancer—A Biomarker or a Surrogate End Point?—Reply	28